Found: 124
Select item for more details and to access through your institution.
Anakinra as a first-line therapy for systemic juvenile idiopathic arthritis when nonsteroidal anti-inflammatory drug treatment fails: a single-center French retrospective study.
- Published in:
- ARP Rheumatology, 2024, v. 3, n. 4, p. 288, doi. 10.63032/TEVI1838
- By:
- Publication type:
- Article
Neutrophilic urticarial dermatosis without systemic disease: case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever.
- Published in:
- Rheumatology International, 2024, v. 44, n. 11, p. 2569, doi. 10.1007/s00296-023-05351-0
- By:
- Publication type:
- Article
Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
- Published in:
- Rheumatology International, 2022, v. 42, n. 1, p. 81, doi. 10.1007/s00296-021-04997-y
- By:
- Publication type:
- Article
Are YouTube videos enough to learn anakinra self-injection?
- Published in:
- Rheumatology International, 2021, v. 41, n. 12, p. 2125, doi. 10.1007/s00296-021-04999-w
- By:
- Publication type:
- Article
Anakinra Promotes M2 Microglia Activation during the Latent Phase of the Lithium-Pilocarpine Model of Temporal Lobe Epilepsy.
- Published in:
- Journal of Evolutionary Biochemistry & Physiology, 2024, v. 60, n. 2, p. 672, doi. 10.1134/S0022093024020182
- By:
- Publication type:
- Article
Erratum to: Effect of Anakinra on the Gene Expression of Receptors Activated by the Peroxisome Proliferator in the Rat Brain in the Lithium Pilocarpine Model of Epilepsy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Effect of Anakinra on the Gene Expression of Receptors Activated by the Peroxisome Proliferator in the Rat Brain in the Lithium Pilocarpine Model of Epilepsy.
- Published in:
- Journal of Evolutionary Biochemistry & Physiology, 2022, v. 58, n. 2, p. 598, doi. 10.1134/S0022093022020260
- By:
- Publication type:
- Article
Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05374-w
- By:
- Publication type:
- Article
Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1339337
- By:
- Publication type:
- Article
Anakinra in pediatric acute fulminant myocarditis.
- Published in:
- Annals of Intensive Care, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13613-022-01054-0
- By:
- Publication type:
- Article
Anakinra versus etoposide‐based therapy added to high‐dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 3, p. 477, doi. 10.1111/ejh.14030
- By:
- Publication type:
- Article
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 3, p. 458, doi. 10.1111/ejh.14029
- By:
- Publication type:
- Article
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
- Published in:
- PLoS ONE, 2023, v. 18, n. 12, p. 1, doi. 10.1371/journal.pone.0295838
- By:
- Publication type:
- Article
Circulating IL‐6 but not neutrophil extracellular traps levels can predict anakinra effectiveness in patients with severe COVID‐19.
- Published in:
- Journal of Leukocyte Biology, 2022, v. 112, n. 6, p. 1365, doi. 10.1002/JLB.4LT0122-018RR
- By:
- Publication type:
- Article
Long-Term Efficacy of Anakinra in Cryopyrin-Associated Periodic Syndrome: Focus on Destructive Arthropathy.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Anakinra for Treatment of Liver Abscesses in a Patient with a Novel CYBB Variant of Chronic Granulomatous Disease.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis.
- Published in:
- Signa Vitae, 2023, v. 19, n. 5, p. 47, doi. 10.22514/sv.2023.025
- By:
- Publication type:
- Article
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report.
- Published in:
- Scandinavian Journal of Rheumatology, 2023, v. 52, n. 2, p. 230, doi. 10.1080/03009742.2022.2140485
- By:
- Publication type:
- Article
Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6531, doi. 10.3390/ijms22126531
- By:
- Publication type:
- Article
Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6282, doi. 10.3390/ijms22126282
- By:
- Publication type:
- Article
Safety and Efficacy Evaluation of PerkinRA in Comparison with Kineret in Systemic Juvenile Idiopathic Arthritis Patients.
- Published in:
- Biomedical & Biotechnology Research Journal, 2024, v. 8, n. 3, p. 363, doi. 10.4103/bbrj.bbrj_155_24
- By:
- Publication type:
- Article
Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19.
- Published in:
- Northern Clinics of Istanbul, 2023, v. 10, n. 2, p. 189, doi. 10.14744/nci.2022.01047
- By:
- Publication type:
- Article
Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
- Published in:
- Modern Rheumatology, 2017, v. 27, n. 2, p. 350, doi. 10.1080/14397595.2016.1194510
- By:
- Publication type:
- Article
Rapid resolution of protracted febrile myalgia syndrome with anakinra: Report of two cases.
- Published in:
- Modern Rheumatology, 2016, v. 26, n. 3, p. 458, doi. 10.3109/14397595.2014.882221
- By:
- Publication type:
- Article
Anakinra and dexamethasone treatment of idarubicin‐induced mucositis and diarrhoea in rats.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2023, v. 132, n. 6, p. 511, doi. 10.1111/bcpt.13851
- By:
- Publication type:
- Article
The Beneficial Outcome of Subsequent Treatment with Anakinra during the Chronic Phase of Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Report.
- Published in:
- Neurology International, 2023, v. 15, n. 4, p. 1489, doi. 10.3390/neurolint15040097
- By:
- Publication type:
- Article
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
- Published in:
- PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0243961
- By:
- Publication type:
- Article
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review.
- Published in:
- Journal of Rheumatology, 2023, v. 50, n. 1, p. 151, doi. 10.3899/jrheum.220213
- By:
- Publication type:
- Article
Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C).
- Published in:
- Indian Pediatrics, 2021, v. 58, n. 10, p. 994, doi. 10.1007/s13312-021-2340-1
- By:
- Publication type:
- Article
Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report.
- Published in:
- Clinical Case Reports, 2020, v. 8, n. 12, p. 2990, doi. 10.1002/ccr3.3307
- By:
- Publication type:
- Article
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 11, p. 1383, doi. 10.1007/s10096-023-04661-2
- By:
- Publication type:
- Article
Anakinra reduces lung inflammation in experimental acute lung injury.
- Published in:
- Immunity, Inflammation & Disease, 2022, v. 10, n. 2, p. 123, doi. 10.1002/iid3.548
- By:
- Publication type:
- Article
Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 8, p. 1129, doi. 10.3390/cells12081129
- By:
- Publication type:
- Article
Analysing of The Effects of an Interleukin - 1 Receptor Antagonist and a RNA Polymerase Inhibitor on Neurodegeneration in the Hippocampal Cell Line.
- Published in:
- Cumhuriyet Medical Journal, 2024, v. 46, n. 2, p. 136, doi. 10.7197/cmj.1482552
- By:
- Publication type:
- Article
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA).
- Published in:
- Open Access Rheumatology: Research & Reviews, 2021, v. 13, p. 257, doi. 10.2147/OARRR.S325400
- By:
- Publication type:
- Article
Successful treatment of pyoderma gangrenosum associated with IgA gammopathy with the IL‐1 receptor antagonist anakinra.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2021, v. 35, n. 7, p. e447, doi. 10.1111/jdv.17204
- By:
- Publication type:
- Article
Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART).
- Published in:
- 2021
- By:
- Publication type:
- journal article
An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
- Published in:
- 2022
- By:
- Publication type:
- Letter
Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
REAL-LIFE COMPARISON OF TOCILIZUMAB AND ANAKINRA ASSOCIATED WITH CORTICOSTEROID USE IN A COHORT OF HOSPITALIZED PATIENTS WITH SARS-CoV-2 INFECTION.
- Published in:
- Farmacia, 2022, v. 70, n. 1, p. 17, doi. 10.31925/farmacia.2022.1.3
- Publication type:
- Article
The Factors Affecting the Efficacy of Interleukin-1 Receptor Antagonists in COVID-19 Patients.
- Published in:
- Journal of Ankara University Faculty of Medicine / Ankara Üniversitesi Tip Fakültesi Mecmuasi, 2022, v. 75, n. 3, p. 400, doi. 10.4274/atfm.galenos.2022.49354
- By:
- Publication type:
- Article
The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis.
- Published in:
- Infection & Chemotherapy, 2021, v. 53, n. 2, p. 221, doi. 10.3947/ic.2021.0016
- By:
- Publication type:
- Article
Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 10, p. 2036, doi. 10.3390/v15102036
- By:
- Publication type:
- Article
Kineret<sup>®</sup>/IL-1ra Blocks the IL-1/IL-8 Inflammatory Cascade during Recombinant Panton Valentine Leukocidin-Triggered Pneumonia but Not during <i>S. aureus</i> Infection.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0097546
- By:
- Publication type:
- Article
Late Acute Cellular Rejection After Anakinra Treatment in a Kidney Transplant Patient, Is It a Coincidence?
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights.
- Published in:
- CTS: Clinical & Translational Science, 2019, v. 12, n. 4, p. 371, doi. 10.1111/cts.12622
- By:
- Publication type:
- Article
Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review.
- Published in:
- BMC Infectious Diseases, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12879-024-09581-w
- By:
- Publication type:
- Article